Nanoparticle Formulations of Diagnostic Agents for Medical Imaging by WANG YAN
  
 
NANOPARTICLE FORMULATIONS OF DIAGNOSTIC 

















NANOPARTICLE FORMULATIONS OF DIAGNOSTIC 







(B. Eng, Shanghai Jiao Tong University) 
 
 
A THESIS SUBMITTED 
FOR THE DEGREE OF MASTER OF SCIENCE 
 
GRADUATE PROGRAMME IN BIOENGINEERING 





I would like to express my sincere appreciation to my supervisor, A/P Feng Si-Shen, for 
his wise guidance, effective support, and patient encouragement throughout this project. 
His great passion to science and serious style of work give me a deep impression that will 
benefit me a lot in my future work. 
 
I would also like to thank Dr Chen Yan, visiting scholar from Curtin University of 
Technology, Australia, my co-supervisor A/P Wang Shih-Chang and A/P Sheu Fwu-Shan, 
MRI specialist Shuter Borys, and all my colleagues in Chemotherapeutic Engineering 
Lab for their continuous guidance and useful advice. 
 
Thanks also go to my parents, my husband and my friends. Without their help and 
encouragement, this project would have been more difficult. 
 
Finally, I wish to express my gratitude to National University of Singapore for providing 
me such a good chance to pursue my research in Singapore. Being exposed to the frontier 







Table of Contents 
 
Acknowledgements.............................................................................................................. I 
Table of Contents................................................................................................................II 
Summary ........................................................................................................................... VI 
List of Tables ................................................................................................................. VIII 
List of Figures ................................................................................................................ VIII 
List of Abbreviations ........................................................................................................ XI 
 
Chapter 1 Introduction..................................................................................................... 1 
1.1 Background......................................................................................................... 1 
1.2 Objectives ........................................................................................................... 2 
1.3 Thesis Organization ............................................................................................ 3 
 
Chapter 2 Literature Review............................................................................................ 4 
2.1 Cancer ................................................................................................................. 4 
2.1.1 Introduction to cancer ................................................................................. 4 
2.1.2 Cancer diagnosis and therapy ..................................................................... 4 
2.2 Nanotechnology in Cancer Diagnosis................................................................. 5 
2.3 Magnetic Nanoparticles in Cancer Diagnosis..................................................... 6 
2.3.1 Basic principles of MRI.............................................................................. 8 
2.3.2 Important parameters of MRI ..................................................................... 9 
2.3.3 MRI contrast agent.................................................................................... 11 
2.3.4 Current research on magnetic polymeric nanoparticles in MRI ............... 13 
 III
2.4 QDs in Cancer Diagnosis.................................................................................. 18 
2.4.1 Properties of QDs...................................................................................... 18 
2.4.2 Current research on QDs loaded polymeric nanoparticles in medical 
imaging 19 
2.5 Nanoparticle Technology.................................................................................. 21 
2.5.1 Nanoparticle formulations ........................................................................ 21 
2.5.2 Characterization of nanoparticles ............................................................. 24 
 
Chapter 3 Materials and Methods.................................................................................. 25 
3.1 Superparamagnetic IOs Loaded PLGA-mPEG Nanoparticles ......................... 25 
3.1.1 Materials ................................................................................................... 25 
3.1.2 Preparation of IOs loaded PLGA-mPEG nanoparticles............................ 26 
3.1.3 Physicochemical characterization............................................................. 27 
3.1.4 MR characterization.................................................................................. 31 
3.2 QDs Loaded Polymeric Nanoparticles.............................................................. 32 
3.2.1 Materials ................................................................................................... 32 
3.2.2 Preparation of QDs loaded polymeric nanoparticles ................................ 33 
3.2.3 Physicochemical characterization............................................................. 33 
3.2.4 Cellular and animal experiments .............................................................. 36 
 
Chapter 4 Superparamagnetic IOs Loaded PLGA-mPEG Nanoparticles as MRI 
Contrast Agent .................................................................................................................. 39 
4.1 Physicochemical Characteristics of the Nanoparticles ..................................... 39 
4.1.1 Characterization of the IOs ....................................................................... 39 
 IV
4.1.2 Particle size and size distribution.............................................................. 40 
4.1.3 Surface morphology.................................................................................. 42 
4.1.4 TEM .......................................................................................................... 43 
4.1.5 Magnetic properties .................................................................................. 43 
4.1.6 Stability ..................................................................................................... 48 
4.1.7 In vitro release........................................................................................... 49 
4.2 MR Characteristics of the Nanoparticles .......................................................... 50 
4.2.1 In vitro MRI .............................................................................................. 50 
4.2.2 Ex vivo MRI .............................................................................................. 54 
 
Chapter 5 QDs loaded PLGA Nanoparticles as Fluorescent Probe............................... 56 
5.1 Physicochemical Characteristics of the Nanoparticles ..................................... 56 
5.1.1 Particle size and size distribution.............................................................. 56 
5.1.2 Surface morphology.................................................................................. 57 
5.1.3 Localization of QDs in PLGA nanoparticles by TEM.............................. 58 
5.1.4 Localization of QDs in PLGA nanoparticles by CLSM ........................... 59 
5.1.5 Fluorescence emission spectrum............................................................... 60 
5.2 Cellular and Animal Experiments..................................................................... 61 
5.2.1 Cell uptake ................................................................................................ 61 
5.2.2 Ex vivo fluorescence imaging ................................................................... 62 
 
Chapter 6 Comparison of QDs Loaded Nanoparticles of Different Biocompatible and 
Biodegradable Polymers ................................................................................................... 64 
6.1 Comparison of Physicochemical Properties of the Nanoparticles.................... 64 
 V
6.1.1 Particle size and size distribution.............................................................. 64 
6.1.2 Zeta potential ............................................................................................ 67 
6.1.3 Surface morphology.................................................................................. 67 
6.1.4 TEM .......................................................................................................... 71 
6.1.5 In vitro release........................................................................................... 73 
6.2 Cellular and Animal Experiemtns..................................................................... 76 
6.2.1 Cell uptake ................................................................................................ 76 
6.2.2 Cell viability.............................................................................................. 80 
 
Chapter 7 Conclusions and Recommendations ............................................................. 82 
7.1 Conclusions....................................................................................................... 82 
7.2 Recommendations............................................................................................. 83 
 













This project is to prepare and evaluate nanoparticles formulated by encapsulating 
diagnostic agents, superparamagnetic iron oxide (IOs) and quantum dots (QDs), into 
matrix of biocompatible and biodegradable polymers, which could potentially reduce the 
toxicity, and increase the imaging efficiency and cell uptake efficiency of the diagnostic 
agents. The nanoparticles were prepared either by water-in-oil-in-water double emulsion 
method or oil-in-water solvent evaporation method. Their physicochemical properties 
were characterized by various techniques including laser light scattering technique for 
particle size, zeta potential analysis for surface charge, field emission scanning electron 
microscopy and atomic force microscopy for surface morphology, transmission electron 
microscopy for qualitative determination of diagnostic agents encapsulated, inductively 
coupled plasma-mass spectrometry and micro-plate reader measurement for quantitative 
determination of the amount of the diagnostic agents loaded, vibrating sample 
magnetometer and superconducting quantum interference device for magnetization and 
magnetic resonance imaging (MRI) for contrast efficiency measurement of the IOs 
loaded nanoparticles, and micro-plate reader measurement for emission spectrum of the 
QDs loaded nanopartilces. Furthermore, in vitro release of the diagnostic agents from the 
polymeric nanoparticles was studied and potential applications of these nanoparticles for 
medical imaging in vitro and ex vivo were also investigated using MCF-7 cell line and 
Sprague Dawley rat. 
 
IOs loaded poly(lactide-co-glycolide)-methoxy poly(ethylene glycol) (PLGA-mPEG) 
nanoparticles are spherical, have a narrow size distribution and show slow IOs release in 
 VII
vitro. Compared with the raw IOs (commercial contrast agent Resovist®), the prepared 
nanoparticles render increased saturation magnetization, r2 and r2* relaxivities, thus 
improved contrast effect for both in vitro and ex vivo MR images. Therefore these 
nanoparticles could become a potential contrast agent for MRI. 
 
QDs loaded poly(D, L-lactide-co-glicolide) (PLGA) and poly(lactide-co-glicolide)-
tocopheryl polyethylene glycol succinate (PLGA-TPGS) nanoparticles were formulated 
and evaluated. Two emulsifiers: polyvinyl alcohol (PVA) and Vitamin E tocopheryl 
polyethylene glycol succinate (VE TPGS) were also compared. The nanoparticles are 
spherical, relatively uniform, of low toxicity and show emission spectrum similar to that 
of free QDs. Among all the formulations, nanoparticles made of PLGA-TPGS copolymer 
(emulsified by PVA) have the slowest QDs release in vitro, lowest cytotoxcity, highest 
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Chapter 1 Introduction 
 
1.1 Background 
Recent progress in cellular and biomolecular techniques has made remarkable changes on 
the way of cancer diagnosis and therapy. In order to understand the mechanisms of 
various cancers and realize early detection, great efforts have been put towards the 
development of reliable, noninvasive and high-resolution medical imaging technology. 
 
Traditional medical imaging focuses on the final manifestation of diseases, while modern 
cellular imaging targets the cellular abnormalities that underlie diseases. The latter is 
defined as using a system in combination with image analysis tools to visualize and 
characterize cells, subcellular structures and biological processes (Weissleder & 
Mahmood, 2001; Lang et al., 2006). This direct imaging of the underlying cellular 
alterations which people currently define as “pre-disease states” allows early detection of 
the diseases. Moreover, the progress and effects of the therapy could also be monitored 
shortly after it has been initiated. 
 
Main techniques in cellular imaging include wide field fluorescence microscopy and 
confocal laser scanning microscope (CLSM), both of which utilize fluorescent molecules 
(fluorophores). Recently, several groups suggest that magnetic resonance imaging (MRI) 
also has a wide range of applications in cellular and biomolecular imaging (Weissleder, 
2002; Lanza et al., 2002; Massoud & Gambhir, 2003).  
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However, some factors have become the bottle-necks for the further applications of 
cellular imaging, one of which is the unstable, ineffective, toxic, and high-cost diagnostic 
agents (Bulte et al., 2002). One of the future improvements may come from the 
development of efficient diagnostic agents. 
 
1.2 Objectives  
To develop stable, efficient and low-toxic diagnostic agents for MRI and fluorescence 
imaging, superparamagnetic iron oxides (IOs) and quantum dots (QDs) were encapsulate 
within matrix of biocompatible and biodegradable polymers. Experiments were carried 
out to investigate the feasibility of the obtained nanoparticles for delivery of diagnostic 
agents in vitro and ex vivo. 
 
To know the effects of polymer matrix and emulsifier on the properties of the diagnostic 
agents loaded nanoparticles, three polymers: poly(D, L-lactide-co-glicolide) (PLGA), 
poly(lactide-co-glycolide)-methoxy poly(ethylene glycol) (PLGA-mPEG), and 
poly(lactide-co-glicolide)-tocopheryl polyethylene glycol succinate (PLGA-TPGS) were 
compared. And two emulsifiers: polyvinyl alcohol (PVA) and vitamin E tocopheryl 
polyethylene glycol succinate (VE TPGS) were tried during the fabrication process.  
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1.3 Thesis Organization 
The thesis is made up of seven chapters. Chapter 1 gives a brief introduction to the 
project. Chapter 2 is a literature review on nanotechnologies in cancer diagnosis. In 
Chapter 3, the materials and methods used in the experiments are described. The 
experimental results and discussions are presented in Chapter 4 to 6, followed by 
conclusions drawn from this project and some recommendations in Chapter 7. 
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Chapter 2   Literature Review 
 
2.1 Cancer 
2.1.1 Introduction to cancer 
Cancer is caused by uncontrolled growth and spreading of abnormal cells. It can 
seriously threaten human health and is a leading cause of death in the world (Feng & 
Chien, 2003). Every year, nearly 1.4 million Americans are diagnosed with cancer 
and another 600 thousand people die from it. The mechanisms of formation and 
spreading of cancers are still not well understood. But both internal factors, such as 
inherited metabolism mutations, immune conditions and hormones, and external 
factors, such as smoking, chemicals, infections and radiation, are believed to be 
relevant. These factors may act together or sequentially to initiate and promote 
carcinogenesis. There is clear evidence that the incidence of cancer can be reduced by: 
1) appropriate nutrition and physical activity, 2) controlled tobacco, alcohol usage, 
obesity and sun exposure, 3) regular cancer screening (American Cancer Society, 
2002). 
 
2.1.2 Cancer diagnosis and therapy 
In the process of cancer diagnosis and therapy, early detection, complete surgical 
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removal, and effective radiotherapy, chemotherapy and other treatments are critical 
factors. Among these, early and precise detection is most important, as it may take 
more than 10 years from the initiation of cell mutation to the formation of cancer. 
Nowadays, there is no thorough cure for a cancer at late stage, but generally an early 
stage cancer is curable and the prognosis can be great. At present, a worthy method is 
to develop a sensitive and reliable cancer diagnosing technology to improve the 
cancer cure rate.  
 
Current cancer diagnosis methods are at tissue level, which has low efficiency and is 
unable to detect initial cancer cells. Efficient diagnosing of cancer at its cellular and 
biomolecular stage has long been a goal for oncologists. Revolutions in cell biology, 
genomics and proteomics have made us closer to it. Cellular and biomolecular 
labeling by nanoparticles is a potential key.  
 
2.2 Nanotechnology in Cancer Diagnosis 
Nanotechnology opens the door to a new generation of cancer diagnosis. It enables 
researchers to create nano-sized particles that contain diagnostic agents and drugs 
designed to image and kill cancer cells, respectively, at the early stage. “The future of 
oncology and the opportunity to eliminate the suffering and death due to cancer will 
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hinge on our ability to confront cancer at its molecular level,” said Andrew von 
Eschenbach, former director of the US National Cancer. Unlike previous revolutions 
in the fighting against cancers that raised hopes, nanotechnology “is not just one more 
tool, it’s an entire field and will pervade everything in medicine,” said Mauro Ferrari, 
a cancer nanotechnology expert at Ohio State University, US. 
 
2.3 Magnetic Nanoparticles in Cancer Diagnosis 
Recently, there has been a great interest in the use of magnetic nanoparticles for 
biomedical applications, namely drug delivery, hyperthermia and MRI contrast 
enhancement (Pankhurst et al., 2003; Gupta & Gupta, 2005). The huge potential of 
these magnetic nanoparticles in biomedicine is due to their special properties. Firstly, 
they have controllable sizes from a few nanometers up to tens of nanometers, 
comparable to or smaller than a protein (5-50nm), a virus (20-450nm) or a cell (10-
100µm), enabling them to get close to these biological entities. Secondly, the 
magnetic nanoparticles can be manipulated by an external magnetic field and thus 
realize “action at a distance” (Pankhurst et al., 2003). 
 
In the field of drug delivery, drug loaded magnetic nanoparticles are used to achieve 
site-specific drug delivery. The nanoparticle has a magnetic core, such as magnetite 
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(Fe3O4), coated with biocompatible polymer. Once the nanoparticles are injected 
into the blood stream, an external magnetic field is used to concentrate the 
nanoparticles at specific sites in the body, where the drug can be released via various 
mechanisms and even the nanoparticles can be taken by the malignant cells. The 
major advantage of this nanoparticle formulation over other chemotherapeutic 
systems is its site-specific targeting and thus low toxicity to the surrounding healthy 
tissues. 
 
Hyperthermia is used to treat cancers by heating abnormal cells while sparing 
surrounding normal tissues. The procedure involves concentrating magnetic 
nanoparticles at the target sites and then applying an alternating magnetic field of 
sufficient strength and frequency to cause the nanoparticles to heat. This heat 
conducts into the immediately surrounding malignant cells, and if the temperature is 
maintained above the therapeutic threshold of 42◦C for 30min or more, the abnormal 
cells will be killed. 
 
However, both the applications of the magnetic nanoparticles in drug delivery and 
hyperthermia depend on the precise detection of the malignant cells, which could 
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also be realized by these magnetic nanoparticles if they are pre-modified with some 
ligands and antibodies for tumor targeting. 
 
Furthermore, magnetic nanoparticles have been developed as MRI contrast agents to 
improve the contrast between healthy and malignant cells. This application is one of 
the focuses of this project and will be further discussed in the following sections. 
 
2.3.1 Basic principles of MRI 
Over the past twenty years, MRI has emerged as one of the most important imaging 
techniques to produce high quality 3D images inside the body of any living thing. It 
relies on the different relaxation times of hydrogen protons in biological tissues, 
which lead to measurable signals in the presence of an external magnetic field. It is 
non-invasive, free of ionizing radiation hazard, and provides great technical 
flexibility as it can be tuned to look at particular tissues (Keevil, 2001).  
 
Spin is a fundamental property of hydrogen protons. It comes in multiples of 1/2 and 
can be either positive or negative. The net magnetization moment vector M is the 
vector sum of all magnetization moments of protons. In the absence of an external 
magnetic field, the magnetization moments of protons are randomly oriented. 
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However, when an external magnetic field Bo is applied in a direction defined as z, 
the protons will be aligned either parallel or antiparallel to the magnetic field with 
proton population of Nl for low energy protons and Nh for high energy protons, 
respectively. The population difference is estimated by Boltzmann’s equation: 





where ∆E is the energy difference between the two states, T is absolute temperature 
in Kelvin, and k is Boltzmann constant.  
In the presence of the magnetic field Bo, before radio frequency (RF) perturbation, 
M vector points in the z direction and there is no net magnetization moment in x- or 
y-axis (Mx = My = 0). The angle between M and Bo is defined as the flip angle. Upon 
perturbation, Mz decreases and Mxy increases until Mz becomes zero and flip angle 
becomes 90◦. This point is called saturation point, at which Mxy peaks off at the 
amplitude of Mz’s previous peak and circles the z-axis at a fixed radius M = Mxy. 
The reverse occurs upon removal of the RF perturbation (Hornak, 1996) and the 
process is referred as relaxation. 
 
2.3.2 Important parameters of MRI 
2.3.2.1 T1 relaxation time  
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The spin-lattice relaxation time T1 (longitudinal relaxation time) is the time taken by 
Mz to return back to Mz0, after RF is removed, which is described as: 
0
1




−= − , 
where Mz0 is the maximum magnetization moment Mz could reach. 
 
2.3.2.2 T2 and T2* relaxation time  
The spin-spin relaxation time T2 (transverse relaxation time) measures the time 







−= ,  
where Mxy0 is the maximum magnetization moment Mxy could reach. Mxy goes to 
zero and then Mz grows until it reaches Mz0. T2 is always less than or equal to T1. 
 
Actually, two factors contribute to the decay of transverse magnetization moment: 
molecular interactions leading to a pure T2 molecular effect, and variations in Bo 
leading to an inhomogeneous T2 effect. The combination of these two factors results 




= +  
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2.3.3  MRI contrast agent 
MRI is normally used for 3D scan of soft tissues and cartilages, and its signal is 
affected by the interaction of the hydrogen proton density and the magnetic 
properties of the tissues being imaged. Different tissues may have different 
relaxation times, thus can be differentiated. However, in many clinical situations, the 
intrinsic differences are so small that the use of contrast agents is required. The 
presence of contrast agents within one tissue allows an intensified difference 
between it and the surrounding to be obtained, either by brightening (positive 
contrast) or darkening it (negative contrast) (Mornet et al., 2005).  
 
Currently, there are two classes of contrast agents according to the magnetic 
properties: 1) paramagnetic, gadolinium (Gd) complexes (e.g. Gd-EDTA, Gd-DTPA, 
Gd-DOTA, ferric ammonium citrate and gadodiamide) as positive contrast agents; 2) 
superparamagnetic, IOs (e.g. Fe3O4 and γ-Fe2O3) as negative contrast agents. 
Functioning of contrast agents is to vary the relaxation time of hydrogen protons in 
various tissues, which is caused by many oscillating fields when the contrast agents 
tumble through a water environment. Superparamagnetic IOs are able to cause a 
remarkable shortening in T2 and T2* of protons while paramagnetic contrast agents 
affect mainly on T1. Since decreased T2 and T2* would result in signal loss, the 
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tissue containing superparamagnetic IOs appears hypointense (dark) relative to the 
surrounding tissues in MR images (Pereira et al., 2003). 
 
The effectiveness of a contrast agent is measured by its r1, r2 or r2* relaxivity 
( 1 1mM s− −⋅ ), which is defined as the gradient in the linear plot of relaxation rate 
against concentration of contrast agent: 
0R R r C= + ⋅ , 
where R = 1/T (s-1) is the proton relaxation rate in the presence of contrast agent, R0 
is that in the absence of contrast agent, and C (mM) is the concentration of contrast 
agent (Chambon et al., 1993). In order to obtain relaxivities of contrast agent using 
MRI, images have to be taken at different time of repetition (TR) and time to echo 
(TE). 
 
Two factors that affect relaxation rates and determine the regime they operate in 
(either motional averaging regime (MAR) or static dephasing regime (SDR)) are 
magnetization of the IOs and diffusion time of water molecules in the surrounding 
medium (Gillis et al., 2002). Magnetization of IOs is directly correlated to their size: 
the larger the particle size, the stronger the magnetization. When particle size of the 
IOs is small and diffusion time of the water molecules is short, IOs can be assumed 
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in MAR. In this regime, relaxation rates increase linearly with the particle size. 
When IOs are large enough and the diffusion time is so long that the water 
molecules are effectively motionless, the IOs are in SDR. In this regime, the 
maximum relaxation rates are achieved. 
 
2.3.4 Current research on magnetic polymeric nanoparticles in MRI 
At present, a range of superparamagnetic IO contrast agents have been developed, 
consisting of small Fe3O4 or γ-Fe2O3 core of less than 10nm and inorganic or 
organic coating (such as dextran, starch, albumin, silicones and polyethylene glycol) 
with hydrodynamic particle size from 10 to 500nm. Some of them have been 
approved for clinical use and are marketed under the trade names such as Lumirem®, 
Endorem®, Sinerem® and Resovist®. They are characterized by displaying a large 
magnetization moment which greatly exceeds that of typical paramagnetic contrast 
agents in the presence of an external magnetic field. And they have no remnant 
magnetization moment once the external field is withdrawn. 
 
The efficacy of the superparamagnetic IOs as a MRI contrast agent depends on:  
1) size. There is a critical particle size (15nm), below which the IO particle consists 
of a single magnetic domain. In other words, the particle is in a state of uniform 
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magnetization at any field with superparamagnetism and high saturation 
magnetization (Ms) (Chatterjee et al., 2003).   
2) superparamagnetic chatacteristics (Tartaj & Morales, 2003).  
3) magnetic susceptibility (Jordan et al., 2001). Superparamagnetic IOs have almost 
50 times greater magnetic susceptibility than gadolinium chelates do.  
4) customized surface chemistry for particular biomedical applications (Moghimi et 
al., 2001).  
 
The major applications of the superparamagnetic IO contrast agents include imaging 
of blood, gastrointestinal (GI) tract, liver, spleen, breast, lymph nodes and bone 
marrow, and perfusion imaging for brain or myocardial ischemic diseases. Unlike 
the healthy liver, tumors contain very little Kupffer cells. Since after injection IOs 
will accumulate in reticuloendothelial system of the Kupffer cells, the tumor region 
will appear bright while the healthy liver will be dark in MR images (Stark et al., 
1988; Lim et al., 2001). For future applications as cellular and biomolecular markers, 
there is a need to develop special IO contrast agents that could greatly increase the 
contrast effect of the MR images as the inherent sensitivity of MRI is considerably 
low compared with the traditional optical and nuclear imaging technologies.   
 
 15
However, the comparatively high toxicity of the IOs puts restrictions on their 
widespread applications. As a result, much attention has been paid to the 
encapsulation of IOs within biocompatible and biodegradable polymers, such as 
poly(D,L lactide) (PLA), poly(glycolide) (PGA) and PLGA (Chatterjee et al., 2002; 
Zhitomirsky et al., 2003; Jeong et al., 2004). The wide choice of these synthetic 
polymers makes it an attractive option over their natural counterparts. Two or three 
monomers can be copolymerized with a defined ratio, which then give rise to a new 
kind of copolymer (Ranade & Hollinger, 2004). In addition, it is hoped that the 
parameters of the nanoparticle formulation process could be optimized so as to retain 
or even improve the superparamagnetic properties of the IOs. Several works have 
been done to demonstrate that carriers of biocompatible and biodegradable polymers 
are ideal because of their low toxicity and immunological response (Mauduit et al., 
1993a; Mauduit et al., 1993b; Mauduit et al., 1993c; Sah & Chien, 1995; Muller et al., 
1996). This way, the systemic side effects of the contrast agents could also be 
minimized as the sustaining local concentration of the free contrast agents is low, 
which may bring us one step closer to the “Magic Bullet”, a concept introduced by 
Paul Ehrlich as early as 1906 (Neuberger et al., 2005). Gomez-Lopera et al. (2001) 
formulated composite particles by coating magnetite with PLA and found decreased 
Ms after the polymer coating. Both Lee et al. (2004) and Ngaboni Okassa et al. (2005) 
 16
encapsulated IOs into PLGA polymer matrix. The former suggested that a decrease in 
particle size might increase the magnetic susceptibility of the nanoparticles as a result 
of the increase in packing density or volume fraction, while the latter did not report 
any magnetization properties of the prepared nanoparticles. Other polymers were also 
used to encapsulate IOs. Dresco et al. (1999) synthesized magnetite loaded polymeric 
nanoparticles using methacrylic acid and hydroxyethyl methacrylate, but they 
assumed that the magnetic susceptibility of magnetite did not change after the 
polymer encapsulation. Pich et al. (2005) prepared composite 
poly(styrene/acetoacetoxyethyl methacrylate) particles with IOs loaded and Zheng et 
al. (2005) incorporated up to 40% (w/w) of 8nm magnetite particles into polystyrene 
nanospheres with an average diameter of 80nm. These works have addressed issues of 
cytotoxicity and investigated physicochemical properties of the formulated particles 
such as particle size, surface morphology and magnetization. Magnetization of the 
nanoparticles is important but it is not a direct indication of the contrast efficacy. 
Releasing of the IOs from the nanoparticles also plays a crucial role in their 
diagnostic efficiency in vitro and in vivo. So far, none of the research groups have 
measured both Ms and relaxivities, or in vitro release profile of the IOs loaded 
polymeric nanoparticles, let alone carrying out a systemic study. Although Pouliquen 
et al. (1989) have conducted MRI measurement of the composite particles, they did 
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not study their magnetization. In addition, their formulated particles were in the 
micron range and produced decreased MRI relaxivities. But our IOs loaded mPEG-
PLGA nanoparticles present increased Ms and r2 and r2* relaxivities. 
 
Encapsulation of IOs within polymer matrix also allows surface modification to 
prolong their blood circulation time, and attachment of targeting ligands to achieve 
site-specific delivery. It is known that long time circulating nanoparticles can be 
obtained by coating the nanoparticles with polyethene glycol. These modified 
nanoparticles have shown to passively target tumors through enhanced permeability 
and retention (EPR) effect (Mareda, 2001; Sahoo et al., 2002). For active targeting, 
ligands, such as folic acid and lectin, whose receptors are over expressed in certain 
tumor cells, have been tried to link to the surface of the nanoparticles (Aronov et al., 
2003; Bies et al., 2004). Surface coating of the nanoparticles also helps them to get 
across some physiological barriers. One example is the use of polysorbates to coat 
nanoparticles so that they could cross the blood brain barrier (BBB) (Alyautdin et al., 
1997; Kreuter et al., 2003; Sun, 2004; Kreuter, 2005). 
 
In clinical practice, MRI is commonly used to distinguish between pathological and 
healthy tissues. However, in the context of chemotherapeutic study, the technology 
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can also be used to monitor drug delivery and its distribution in animals without 
sacrificing them. This can be done by encapsulating drugs together with the MRI 
contrast agents into the polymer matrix. 
 
2.4 QDs in Cancer Diagnosis 
2.4.1 Properties of QDs 
QDs are semiconductor nanocrystals with unique electrical and optical properties, 
ranging in size from 1 to 100nm (Pinaud et al., 2006). Recently, QDs seem to be a 
great alternative to replace the conventional fluorescent probes for medical imaging. 
This is because of the advantages QDs have (Alivisatos, 1996; Chen & Rosenzweig, 
2002; Chan et al., 2002), such as: 
1) size- and composition-tunable emission from visible to infrared wavelength. 
2) narrow and symmetrical emission peak, and broad excitation spectrum, which 
allow simultaneous detection of multiple signals. 
3) large extinction coefficient, resulting in high level of brightness. 
4) large Stokes shift (defined as the distance between excitation peak and emission 
peak), which can be as large as 300-400nm, becomes especially important for in vivo 
cellular and biomolecular imaging. Signals of traditional organic dye with small 
Stokes shift are often buried by strong auto-fluorescence of the tissues while those of 
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the QDs could be clearly recognized from the background. 
5) photostability, such as resistance to photobleaching, is favorable when cells or 
animals are to be observed for a long period of time. 
 
Besides being used as fluorescent probes, QDs also have the potential to act as 
photosensitizing agents (photosensitizers) in photodynamic therapy (PDT) (Gao et al., 
2005). When exposed to a specific wavelength of light, QDs can induce the formation 
of peroxide and other free forms of radicals which can kill nearby cells. This is 
especially useful if QDs could de designed to target cancer cells. 
 
2.4.2 Current research on QDs loaded polymeric nanoparticles in medical imaging 
QDs have drawn significant attention because of their special properties in the past 
decade, and their applications in medical imaging have been explored by many 
scientists. However, their wide applications have been limited by the facts that QDs 
are toxic, water insoluble, bio-incompatible, chemically instable, and do not have 
functional groups for conjugation with biomolecules (Chan et al., 2002; Dubertret et 
al., 2002). Recent works have shown that QDs are highly toxic to cells under UV 
irradiation as it might destroy the semiconductor particles and release toxic cadmium 
(Cd) ions into the surrounding medium (Derfus et al., 2004). QDs are often coated 
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with zinc sulfide (ZnS) to reduce the toxicity, but only to a certain extent. In the 
absence of UV irradiation, Gao et al. (2004) found that QDs with a stable polymer 
coating were essentially nontoxic to cells in vitro (having no effect on cell division or 
ATP production). This was probably because of the polymer layer that isolated the 
QDs cores from the outside environment. 
 
Over the years, researchers have had considerable interests in modifying the surface 
of QDs and in developing polymer matrix containing QDs, to minimize their 
disadvantages. A summary of various methods that have been employed to alter the 
surface properties of the QDs could be found in Medintz et al.’s review paper (2005). 
However, polymer encapsulated QDs are particularly attractive because of their 
processibility and functionality (Wang et al., 2004). QDs have been incorporated into 
polystyrene and silica micro/nanoparticles by emusion polymerization method (Yang 
& Zhang, 2004), and also been incorporated into PLA nanoparticles by 
nanoprecipitation method (Guo et al., 2006). Gao et al. (2004; 2005) coated the QDs 
with amphiphilic triblock copolymer for in vivo protection, ligands for tumor 
targeting, and PEG molecules for enhanced biocompatibility and circulation time. 
And these QDs loaded nanoparticles were demonstrated to be able to actively target 
tumor cells and allow multicolor imaging in living animals.  
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2.5 Nanoparticle Technology 
2.5.1 Nanoparticle formulations  
There are quite a number of methods to formulate nanoparticles. In general, 
nanoparticles can be formed either by dispersion of polymers or by polymerization 
of monomers. These methods include: solvent evaporation/extraction, solvent 
diffusion/nanoprecipitation, supercritical fluid spraying, and polymerization of 
monomers. The methods commonly used in the laboratory are solvent evaporation 
and solvent diffusion. 
 
Solvent evaporation method is widely used in the formulation of drug loaded 
polymeric nanoparticles (Feng & Chien, 2003). In this method, the polymer is 
dissolved in an organic solvent, such as dichloromethane (DCM), ethyl acetate and 
chloroform. Diagnostic or therapeutic agents are dispersed in the polymer solution, 
and then the mixture is added to an aqueous solution containing an emulsifier. It is 
necessary to use emulsifier because emulsion formed by mixing two liquids is 
unstable and will quickly separate into distinct phases. Emulsifier helps to lower the 
interfacial tension and reduce the thermodynamic driving force towards 
convalescence (Feng & Huang, 2001; Dong & Feng, 2004). After a stable emulsion 
is formed by ultrasonication, the organic solvent will then be evaporated. 
 22
Subsequent centrifugation is applied to wash and collect the nanoparticles, which 
will finally be freeze-dried to form dry powder of nanoparticles. Note that freeze-dry 
technique is only suitable for laboratory scale operation and that actual large-scale 
production of nanoparticles requires other technologies, such as spray-dry and 
spray-freeze-dry. 
 
In solvent diffusion method, a water-miscible solvent such as acetone or methanol is 
used. Formation of nanoparticles in this method is attributed to the spontaneous 
diffusion of water-miscible solvent, creating an interfacial turbulent flow between 
the aqueous phase and oil phase. After the formation, the nanoparticles would be 
subjected to the same treatments as the solvent evaporation method. 
 
Various polymers were used to formulate nanoparticles using the above methods. 
Some are even FDA-approved biodegradable polymers, such as PLA, PLGA and 
poly(caprolactone) (PCL), but those polymers were originally synthesized to make 
surgical sutures and thus have disadvantages to be used for drugs/diagnostic agents 
formulation, including short blood circulation time, too high hydrophobicity and 
undesirable degradation rate (Zhang & Feng, 2006). Therefore, in this study novel 
copolymer PLGA-mPEG and PLGA-TPGS were used and compared with 
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traditional PLGA. Two emulsifiers: PVA and VE TPGS were tried during the 
fabrication process. These polymers were chosen because they are safe, 
biocompatible and biodegradable since the eventual hydrolysates of the polymers 
are non-harmful (lactic acid, glycolic acid, vitamin E etc) (Gupta & Kompella, 
2006). With PEG and TPGS components added in, hydrophobicity of PLGA could 
be adjusted, which makes the polymers more friendly to hydrophilic 
drugs/diagnostic agents. Because of the hydrophilic surface of superparamagnetic 
IOs, PLGA-mPEG was used to fabricate the nanoparticles. Moreover, PEG was also 
reported to be able enhance blood circulation time, EPR and stability of the 
nanoparticles (Mareda, 2001; Sahoo et al., 2002, Avgoustakis et al., 2003). However, 
for hydrophobic QDs, PLGA was tried initially, and some novel formulations were 
further investigated in Chapter 6. PVA is the most commonly used emulsifier in 
nanoparticle formulations, often resulting in nanoparticles that are small and 
uniform. VE TPGS was chosen because of its masking effect that allowed the 




2.5.2 Characterization of nanoparticles 
The biomedical properties of the diagnostic or therapeutic agents loaded 
nanopartciles depend on their physicochemical characteristics. Therefore, it is 
necessary to characterize various physicochemical properties of the nanoparticles 
using state-of-the-art techniques. More details will be provided in Chapter 3. 
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Chapter 3 Materials and Methods 
 
3.1 Superparamagnetic IOs Loaded PLGA-mPEG Nanoparticles 
3.1.1 Materials 
The superparamagnetic IOs used in this study was a commercial MRI contrast agent 
Resovist®, which is an aqueous suspension consisting of superparamagnetic IOs coated 
with carboxydextran. Resovist® was purchased from Schering AG. Copolymer PLGA-
mPEG (MW = 30,000-500,000) with L:G molar ratio of  80:20 and 4.75% (w/w) PEG 
(MW = 2,000) was synthesized by Mr Dalwadi G from Curtin University of Technology, 
Australia. PVA with MW of 30000-70000 and phosphate buffer solution (PBS) were 
purchased from Sigma. DCM of HPLC grade and 30% hydrogen peroxide Suprapur® 
were purchased from Merck, and concentrated (>69.5%) nitric acid was from Fluka. 
Milli-Q water with resistivity of 18.0MΩ•cm was prepared by Milli-Q Plus System 



















Figure 1 Chemical structures of PLGA-mPEG and PVA. 
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3.1.2 Preparation of IOs loaded PLGA-mPEG nanoparticles 
 
 
Figure 2 Schematic representation of the preparation of IOs loaded PLGA-mPEG nanoparticles by double 
emulsion method. 
 
IOs loaded PLGA-mPEG nanoparticles were prepared by water-in-oil-in-water (w/o/w) 
double emulsion method as illustrated in Figure 2. IO aqueous suspension was added to 
2% (w/v) PLGA-mPEG solution in DCM and sonicated by MICROSONICTM 
ultrasonicator equipped with a microtip probe (XL2000, Misonix Incorporated, US) for 
60s at 25W, to obtain an water-in-oil emulsion. Then, this water-in-oil emulsion was 
poured into 1% (w/v) PVA (as an emulsifier) aqueous solution and sonicated for 90s at 
the same power. Organic solvent was eliminated by evaporation under mechanical 
stirring at room temperature overnight (for 12h). After solvent evaporation, the formed 
nanoparticles were collected by centrifugation (5810R, Eppendorf, 12000rpm, 15min, 
20◦C) and washed with Milli-Q water for three times to remove excessive emulsifier and 
free IOs. To obtain fine powder of the nanoparticles, the nanoparticle suspension was 
freeze-dried using a freeze dryer (Alpha-2, Martin Christ, Germany). Empty PLGA-
mPEG nanoparticles were prepared in the same way by replacing IO aqueous suspension 
with water. 
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3.1.3 Physicochemical characterization 
3.1.3.1 X-ray diffraction (XRD) 
Crystallographic analysis was performed to identify the dominant phase of the IOs by 
XRD machine (Bruker AXS Powder, D8 Advance, US) with a Cu Kα radiation 
(λ=1.54056Å). A monochromatic beam will be scattered, when it impinges on a crystal 
composed of atoms periodically aligned in three dimensions. The coherently scattered X-
rays, which have the same frequency and definite phase difference, interfere with each 
other either constructively or destructively. A diffraction pattern is generated when the 
scattered rays mutually reinforce one another (Cornell & Schwertmann, 1996).  
 
The specimen was prepared by plating the fine powder in the recess of a glass plate and 
then pressed hard to cause cohesion and to smooth off the surface. The phase was 
identified using standard powder diffraction files of JCPDS (Joint Committee for Powder 
Diffraction Studies). 
 
3.1.3.2 Surface chemistry 
X-ray photoelectron spectroscopy (XPS, AXIS His-165 Ultra, Kratos Analytical, 
Shimadzu, Japan) was used to determine the surface properties of the IOs. Together with 
the XRD result, XPS spectrum can tell the major phase of the IOs. Before analysis, the 
powder was attached to a glass piece, which was then stuck on a metal stub using double-
sided sticky tape. After the measurement, the data was processed and curve fitting was 
performed using the software provided by the manufacturer. 
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3.1.3.3 Particle size and size distribution 
Particle size and size distribution of the nanoparticles play a key role in determining their 
fate and diagnostic or therapeutic effects (when diagnostic agents or drugs are 
encapsulated). They are also important in the study of nanoparticles interaction with cell 
membranes and crossing physiological barriers such as BBB and GI tract. 
 
Laser light scattering (LLS) technique was employed to determine the size and size 
distribution of the nanoparticles, with a particle size analyzer (90 Plus, Brookhaven 
Instruments Corporation, US) at a fixed angle of 90° at 25◦C. In brief, the nanoparticles 
were suspended in Milli-Q water and sonicated to form uniform suspension. CONTIN 
was used for the data analysis. 
 
3.1.3.4 Surface morphology 
Field emission scanning electron microscope (FESEM, JSM-6700F, JEOL, Japan) at an 
accelerating voltage of 10kV was used to determine the surface morphology of the 
nanoparticles. Before the observation, nanoparticles were immobilized on metallic studs 
with double-sided conductive tape and then coated by a sputter coater (JFC-1300, JEOL, 
Japan) for 30s in a vacuum at a current intensity of 30mA.  
 
3.1.3.5 Transmission electron microscopy (TEM) 
TEM (JEM 2010F, JEOL, Japan) examinations of the IOs and nanoparticles were carried 
out with an electron kinetic energy of 200kV. A drop of well dispersed IO or nanoparticle 
suspension was placed on a Formvar/carbon 200 mesh copper grid and then dried at 
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ambient condition, before the grid was attached to the sample holder of the microscope. 
 
3.1.3.6 Inductively coupled plasma-mass spectrometer (ICP-MS) 
Iron (Fe) contents of both the IOs and nanoparticles were determined by ICP-MS (Elan 
6100, Perkin-Elmer, US) against standards. In order to completely dissolve the samples 
before analysis, samples were pre-treated using microwave digestion system (1200 
MEGA, Milestone, Germany). In brief, sample, together with 3ml of Milli-Q water, 2ml 
of concentrated nitric acid and 1.5ml of 30% hydrogen peroxide, was added to each 
digestion vessel, and the digestion was performed with the program developed by 
Krachler et al. (1996).  
 
3.1.3.7 Magnetic properties 
Vibrating sample magnetometer (VSM, Lakeshore 7300 Series, US) was used to 
determine the Ms of both the IOs and nanoparticles. The sample was pressed into a small 
pellet with diameter of ~5mm and then attached to the long end of a plastic rod in a 
superconductive solenoid type of electromagnet that could produce a magnetic field of 9T. 
Hysteresis loop, from which Ms could be determined, was obtained by slowly sweeping 
the applied field from maximum positive field, through zero, to a maximum negative 
field, and back again. A small piece of nickel was used as a standard sample to calibrate 
the VSM before the measurement was taken at room temperature.  
 
In order to further investigate the magnetic behaviors of the samples at different 
temperatures, superconducting quantum interference device (SQUID, MPMS XL5, 
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Quantum Design, US) was employed. The temperature-dependent magnetization of the 
sample was obtained by measuring the magnetization in temperature range of 2-400K 
with applied field of 20kOe.  
 
Zero field cooling (ZFC) and field cooling (FC) curves were taken under the applied 
magnetic field of 100Oe at temperature between 2 and 400K, from which blocking 
temperature (TB) of each sample could be obtained. 
 
3.1.3.8 Stability 
Stability of the nanoparticles was evaluated for their resistance to osmotic agent sodium 
chloride (NaCl), which may potentially cause nanoparticle aggregation. 60mg of the 
nanoparticles were added to 20ml of 0.9% saline solution and incubated at 37◦C in an 
orbital shaking water bath (shaking horizontally at 120min-1). Particle size was measured 
after 0, 18, 24 and 48h using LLS. 
 
3.1.3.9 In vitro release 
5mg of the nanoparticles was placed in each centrifuge tube, and dispersed in 10ml of 
PBS (pH = 7.4). The tube was then put into the 37◦C orbital shaking water bath, and 
taken out at particular time intervals. The supernatant was collected by centrifugation at 
10000rpm for 10min for release analysis by ICP-MS. The pellet was re-suspended in 
10ml of fresh PBS and put back to the shaker for continuous measurement. This study 
was carried out in triplicates. 
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3.1.4 MR characterization 
3.1.4.1 In vitro MRI 
MR images of the nanoparticle aqueous suspensions at different concentrations, from 
0mM to 0.5mM, were obtained using a Siemens Symphony 1.5T scanner with a head coil, 
which were compared with those of the raw IO aqueous suspensions. In vitro r2 and r2* 
relaxivities were also measured. Spin echo sequence was used, flip angle = 90○, NEX = 1, 
FOV = 180mm, and slice thickness = 5mm. TR and TE for the relaxivity measurements 
were listed in Table 1. 
 
Table 1 TR and TE for r2 and r2* relaxivity measurements. 
Relaxivity ( 1 1mM s− −⋅ ) TE (ms) TR range (ms) 
2400 [9, 360] r2 
1600 [20, 160] 
2400 [5, 60] r2* 
1600 [5, 60] 
 
3.1.4.2 Ex vivo MRI 
This study was performed according to a protocol conforming to the animal care 
legislation and approved by Institutional Animal Care and Use Committee (IACUC), 
National University of Singapore. Male Sprague Dawley (SD) rats (200-250g) were used. 
IOs loaded PLGA-mPEG nanoparticle suspension in 9% saline solution (0.9mg Fe/ml) 
equivalent to 3.7mg Fe/kg of rat body weight was intravenously injected into the rat 
through tail vein over 300s under anaesthesia. Rat injected with same volume of saline 
solution was used as control. One hour after the injection, the rats were sacrificed under 
anaesthesia and dissected. Livers were imaged by MRI immediately. 
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3.2 QDs Loaded Polymeric Nanoparticles 
3.2.1 Materials 
The red emission hydrophobic QDs (with a maximum emission at 655nm) and modified 
green emission hydrophilic QDs (with a maximum emission at 525nm) used in this study 
were purchased from Invitrogen. Copolymer PLGA-TPGS (MW = ~10,000) with 15% 
(w/w) VE TPGS was synthesized by Mr Zhang Zhiping in our lab. PLGA (MW = 
90,000-125,000) with L:G = 75:25 and Dulbecco's Modification of Eagle's Medium 














































Figure 3 Chemical Structures of PLGA, VE TPGS and PLGA-TPGS. 
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3.2.2 Preparation of QDs loaded polymeric nanoparticles 
The red emission hydrophobic QDs loaded PLGA nanoparticles were prepared by oil-in-
water (o/w) solvent evaporation method as shown in Figure 4. In brief, QDs suspension 
in DCM with 2% of PLGA was poured into 0.5% (w/v) PVA or 0.06% (w/v) VE TPGS 
aqueous solution, and sonicated for 120s at 25W output. Organic solvent was evaporated 
overnight (for 12h) under magnetic stirring at room temperature. After solvent 
evaporation, the formed nanoparticles were processed using the same procedure as 
described in section 3.1.2. 
 




3.2.3 Physicochemical characterization 
3.2.3.1 Particle size and size distribution 
Size and size distribution measurement of the QDs loaded polymeric nanoparticles was 




3.2.3.2 Zeta potential 
Zeta potential is the difference in electrostatic potential between the layer of ions on 
nanoparticle surface and the bulk liquid in which the nanoparticles are suspended. It 
indicates the amount of charge on the surface of the nanoparticles, and is used to predict 
their stability. The bigger the zeta potential, the more stable the nanoparticle suspension, 
because the repulsion between charged nanoparticles prevents the natural tendency of 
aggregation. Furthermore, surface charge also determines whether the nanoparticles will 
agglomerate in blood circulation and how they will interact with cells. The equipment 
used was ZetaPlus Zeta Potential Analyzer (Brookhaven Instruments Corporation, US). 
 
3.2.3.3 Surface morphology 
Surface morphology study of the QDs loaded polymeric nanoparticles was similar to 
those loaded with IOs (refer to section 3.1.3.4 for more details). 
 
Moreover, atomic force microscope (AFM, Nanoscope IIIa, Digital Instrument, Canada) 
was employed to get 3D images of the nanoparticles with high resolution without extra 
coating before observation, and hence the images look more real. Before scanning, the 
sample was fixed on an AFM sample stud with double-sided sticky tape. The scan was 
operated under tapping mode. 
  
3.2.3.4 Localization of QDs in polymeric nanoparticles by TEM 
TEM measurement of the QDs and QD loaded polymeric nanoparticles was similar to 
those loaded with IOs (refer to section 3.1.3.5 for more details). 
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3.2.3.5 Localization of QDs in polymeric nanoparticles by CLSM 
In order to further prove that the red emission hydrophobic QDs have been successfully 
encapsulated into the polymeric nanoparticles, commercially modified green emission 
hydrophilic QDs, together with the red emission hydrophobic QDs, were encapsulated 
into the polymeric nanoparticles using double emulsion technique. In brief, green 
emission hydrophilic QDs aqueous suspension was added to red emission hydrophobic 
QDs suspension in DCM with 2% of the polymer, and sonicated for 60s at 25W output to 
obtain a water-in-oil emulsion. This emulsion was then poured into 0.5% (w/v) PVA 
aqueous solution and sonicated for 90s at the same power. The obtained nanoparticles 
were further treated using the same procedure as in section 3.2.2. After encapsulation, a 
drop of nanoparticle suspension was placed on a glass slide and observed using CLSM to 
co-localize the red emission hydrophobic QDs and green emission hydrophilic QDs in the 
suspension. The red and green signals should not be together in the suspension unless 
both QDs have been successfully encapsulated into one polymeric nanoparticle, as their 
surface properties are contrary. The CLSM measurement was carried out on Olympus 
FV500 (Olympus, Japan) with an imaging software (Fluoview 4.3). 
 
3.2.3.6  Fluorescence  emission spectrum 
Fluorescence emission spectrum is very important to QDs. Spectra of free QDs in n-
decane and nanoparticles aqueous suspension were studied using micro-plate reader 




3.2.3.7 In vitro release 
In vitro release study of the QDs loaded polymeric nanoparticles was similar to those 
loaded with IOs (refer to section 3.1.3.9 for more details). Both PBS and cell culture 
medium DMEM were used, and study was carried out in duplicates. 
 
3.2.4 Cellular and animal experiments 
3.2.4.1 Cell uptake 
For quantitative study, MCF-7 (human breast adenocarcinoma) cells cultured in cell 
culture medium DMEM were seeded in 96-well black plates at ~4*104cells/well. After 
cells reached about 80% confluence, the medium was changed with 100µl medium that 
contained the nanoparticles at the concentrations of 250 or 500mg/ml. A total of 8 wells 
were used for a particular nanoparticle concentration, and of these 8 wells, 4 would 
eventually be washed with PBS and the other 4 wells were left unwashed. One row of 12 
wells was used as control, in which no nanoparticles were added. The cells with 
nanoparticle suspensions were incubated for either 2h or 24h. After incubation, for those 
washed samples, the suspension was removed and the cells were washed three times with 
PBS to eliminate traces of nanoparticles on the surface of the cells, and then 100µl 
medium was added to each well. After that, 50µl 0.5% Triton X-100 in 0.2mol/L sodium 
hydroxide was added to all wells, including control, to lyse the cells and release QDs to 
the medium. The amount of QDs present in each well was then measured by micro-plate 





= × , 
where Iwashed is the intensity of the washed sample after subtraction of the control, and 
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Iunwashed is that of the unwashed sample after subtraction of the control. 
 
For qualitative study, MCF-7 cells were seeded in the chambered cover glass system 
(LAB-TEKs, Nagle Nunc, US). When cells reached about 80% confluence, the medium 
was changed with the medium that contained the nanoparticles at the concentration of 
250mg/ml, and then the cells were incubated for 2h. After incubation, the nanoparticle 
suspension was removed and the cells were washed three times with PBS. The cells were 
then fixed with 80% ethanol for 20min and further washed twice with PBS. After that, 
the nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI) for 40min. 
Lastly, the cell monolayer was washed twice with PBS and mounted in Dakos 
fluorescence mounting medium (Dako, Canada) for the observation by CLSM.  
 
3.2.4.2 Cell viability 
Cell viability of the nanoparticles was assessed by MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay, which is based on the reductive capacity of 
mitochondrial reductase enzymes in living cells to reduce the yellow MTT to purple 
formazan, whose absorbance could be measured by the micro-plate reader.  
 
MCF-7 cells were seeded in 96-well white plates at ~4*104cells/well. When the cells 
were about 80% confluent, the medium was replaced with 100µl medium that contained 
QDs loaded polymeric nanoparticles at the concentrations of 0.5, 5, 50 or 250µg/ml for 
24h incubation. The nanoparticles were sterilized by γ-irradiation for 72h before the test. 
6 wells were used for each sample. One row of 12 wells was used as positive control, in 
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which no nanoparticles were added. After 24h, the nanoparticle suspension was removed 
and the cells were washed twice with PBS, and then 100µl medium was added to each 
well. After that, 90µl medium and 10µl MTT solution were added to all wells, including 
the control, and then the cells were incubated for another 4h. After the incubation, the 
supernatant was removed and 100µl isopropanol was added to each well to dissolve 
formazan crystals. Finally, micro-plate reader was used to measure the absorbance of all 
the samples. One row of 12 wells was used as negative control. The cell viability was 





= × , 
where Abssample is the absorbance of the cells incubated with samples after subtraction of 
the negative control, and Abscontrol is the absorbance of the positive control after 
subtraction of the negative control. 
 
3.2.4.3 Ex vivo fluorescence imaging 
QDs loaded polymeric nanoparticle suspension in 0.9% saline solution was intravenously 
injected into the made SD rat through tail vein over 300s under anaesthesia. Rat injected 
with same volume of saline solution was used as control. One hour after the injection, the 
rats were sacrificed under anaesthesia and dissected. The various tissues were fixed by 
4% paraformaldehyde solution and then frozen using tissue freezer. After that, Cyrostat 
(Leica, CM3050, Germany) was used to cut the frozen tissues into slices of 10µm thick 
for CLSM observation. 
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Chapter 4 Superparamagnetic IOs Loaded PLGA-mPEG 
Nanoparticles as MRI Contrast Agent 
 
4.1 Physicochemical Characteristics of the Nanoparticles 
4.1.1  Characterization of the IOs  
 




























Figure 5 XRD spectrum of the IOs. 
 
XRD was carried out to identify the nanocrystalline structure of the IOs. 
Characteristic peaks in Figure 5 indicate that Fe3O4 or γ-Fe2O3 might be the dominant 
phase of the IOs. Further investigation conducted by XPS (atomic orbital 2p of Fe) 
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demonstrates the presence of both Fe2+ and Fe3+ in the sample, as shown by Peak 1 
(Fe3+) and Peak 2 (Fe2+) in Figure 6. Together with the result of XRD, this XPS 
spectrum confirms that Fe3O4 is the major phase of the IOs. 
 














Figure 6 Fe 2p XPS spectrum of the IOs. 
 
4.1.2 Particle size and size distribution 
Particle size distribution of the IOs loaded PLGA-mPEG nanoparticles is given in 
Figure 7, and the average hydrodynamic size, together with the amount of IOs 
incorporated, is summarized in Table 2.  
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IOs loaded PLGA-mPEG nanoparticles
 
Figure 7 Particle size distribution of IOs loaded PLGA-mPEG nanoparticles. 
 
Table 2 Properties of IOs and IOs loaded PLGA-mPEG nanoparticles. 
Sample Average hydrodynamic diameter 
(nm) 
Fe content±SD (%(w/w)) 
IOs 60 (Kirchin & Runge, 2003) 22.02 ± 2.31 (n=5) 
IOs loaded PLGA-mPEG 
nanoparticles 
233.0 1.37 ± 0.02  (n=5) 
 
The size distribution of the prepared nanoparticles is fairly narrow and the average 
hydrodynamic size is 233.0nm. The particle size is desirable as small particles 
(<500nm) could cross the membrane of epithelial cells through endocytosis and have 
ease of entry and durability in the tumor cells, while large particles (<5µm) would be 
taken up via the lymphatics (Lefevre et al., 1978; Savic et al., 2003; Dong & Feng, 
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2004). Fe loading of the nanoparticles is ~1.37% and that of the raw IOs is ~22.02%. 
This is because of the high weight ratio of the polymer matrix for the prepared 
nanoparticles. From the literature, it is found that the size of the IOs together with the 
coating is approximately 60nm (Kirchin &Runge, 2003), while the IO core is very 
small as can be seen from the TEM image in section 4.1.4. 
 
4.1.3 Surface morphology 
Surface morphology, another crucial property of the IOs loaded PLGA-mPEG 
nanoparticles, was studied using FESEM (Figure 8). These nanoparticles are spherical 




Figure 8 FESEM image of IOs loaded PLGA-mPEG nanoparticles (bar = 1µm). 
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4.1.4 TEM 
Figure 9a & Figure 9b show TEM images of the IOs and IOs loaded PLGA-mPEG 
nanoparticles, respectively. The dark domains in Figure 9b are the IOs incorporated, 
which demonstrates the successful nanoparticle formulation of the IOs. 
 
  
Figure 9 TEM images of (a) IOs (bar = 20 nm),                                                                                  
and (b) IOs loaded PLGA-mPEG nanoparticles (bar = 50 nm). 
 
4.1.5 Magnetic properties  
The difference in magnetization between IOs and IOs loaded PLGA-mPEG 
nanoparticles measured by VSM is presented in Figure 10. Negligible coercivity and 
remanence on the hysteresis loops of both IOs and nanoparticles indicate that after 
polymer encapsulation the superparamagnetic behavior of the IOs remains the same. 
At body temperature of 300K, IOs loaded PLGA-mPEG nanoparticles exhibited Ms 
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of 83.5emu/g, while the raw IOs displayed 72.9emu/g. This could be resulted from 
the agglomeration taking place during the process of the nanoparticle formulation. 
As it is known that magnetization of the IOs is directly correlated to their size: the 
larger the particle size, the stronger the magnetization. Such an improvement in Ms 
is desirable since the MR contrast effect of the IOs will be enhanced as well. 
Actually, a change in magnetization of the IOs after encapsulation by polymer has 
been reported previously, but a decreased Ms was observed (Gomez-Lopera et al., 
2001), probably due to the encapsulation of a single magnetic core instead of a 
cluster of IOs.  
 


















 IOs loaded PLGA-mPEG nanoparticles
 IOs
Hysteresis loops at 300K
 
Figure 10 Magnetizations of IOs and IOs loaded PLGA-mPEG nanoparticles at 300K. 
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SQUID was employed to further study the temperature dependence of the 
magnetization for both IOs and nanoparticles. Generally, an increase in temperature 
results in a decrease in magnetization. This is because as temperature rises, thermal 
motion interferes more strongly with the order produced by the molecular field 
which is responsible for the parallel orientation of the magnetization moments of a 
domain (Gomez-Lopera et al., 2001). Figure 11 also reveals that the higher the 
temperature, the bigger the magnetization difference between the IOs and 
nanoparticles. 
 
























 IOs loaded PLGA-mPEG nanoparticles
 
Figure 11 Magnetization as a function of temperature for IOs and IOs loaded PLGA-mPEG 
nanoparticles (Applied field = 20 kOe). 
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ZFC and FC curves of the IOs and IOs loaded PLGA-mPEG nanoparticles from 2 to 
400K are depicted in Figure 12. It further confirms the superparamagnetic behaviors 
of both the IOs and nanoparticles, because the divergence of the susceptibility 
between ZFC and FC curves is another typical feature of superparamagnetic 
materials (Liu et al., 2000). It could be observed that as temperature increases, the 
ZFC magnetization increases and reaches a peak, where the temperature is known as 
TB. TB is defined as the temperature at which the moments of IOs do not relax 
during the time scale of the measurement (Lin et al., 2006), and it is an important 
parameter in the study of a magnetic particle system (Gupta & Gupta, 2005). Above 
TB, there is sufficient thermal energy to overcome the magnetic anisotropy, and the 
IOs are aligned according to the applied field and exhibit superparamagnetic 
properties. After encapsulation by the polymer, TB has increased from 187K to 212K. 
This is probably due to the agglomeration of IOs inside of the polymer matrix. It is 
known that TB increases with particle size of the IOs, because greater energy is 
required to overcome the anisotropy when the size increases.  
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IOs loaded PLGA-mPEG nanoparticles
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Figure 12 ZFC and FC curves of IOs and IOs loaded PLGA-mPEG nanoparticles                    
(Applied field = 100Oe). 
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4.1.6 Stability 
Stability of IOs loaded PLGA-mPEG nanoparticles was studied by monitoring the 
change of particle size when exposed to 0.9% saline solution at 37◦C. As shown in 
Figure 13, there is no significant size change of the nanoparticles during a period of 2 
days, and the size remains around 250nm, which adds the advantage to the IOs loaded 
PLGA-mPEG nanoparticles to cross the membrane of epithelial cells through 
endocytosis and have ease of entry and durability in the tumor cells (Lefevre et al., 
1978; Savic et al., 2003; Dong & Feng, 2004). Therefore, it could be concluded that 
no noticeable aggregation has occurred and that the nanoparticles are resistance to 
electrolytes in 2 days. This stability of the nanoparticles is suggested to be a result of 
the steric stabilization provided by PEG molecules (Avgoustakis et al., 2003).  



















Time (h)  
Figure 13 Stability of IOs loaded PLGA-mPEG nanoparticles in saline solution at 37◦C. 
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4.1.7 In vitro release 





















IOs loaded PLGA-mPEG nanoparticles 
in vitro release in PBS
 
Figure 14 In vitro release of IOs loaded PLGA-mPEG nanoparticles in PBS. 
 
From the in vitro release profile presented in Figure 14, an initial burst could be 
observed, after which the release rate of the IOs from the nanoparticles is pretty 
constant. At the end of 9 days, about 20% of the IOs is released. Subsequently, there 
is very little IOs release. In fact after 31 days, only 21.3% (SD = 1.8%) of IOs is 
released. The release of IOs from the nanoparticles is inevitable, but it is slow and 
will take a long time, during which the medical imaging purpose would have been 
achieved and most nanoparticles might have been cleared by the body. This slow 
release has an important medical implication because the toxicity of the IOs would be 
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minimized when it is not circulated freely in the blood stream. Hence, the 
nanoparticles hold the potential to be used for prolonged MRI as long as the 
nanoparticles are not cleared from the body.  
 
4.2 MR Characteristics of the Nanoparticles 
4.2.1 In vitro MRI 
Superparamagnetic IOs have been recognized to have great potential in clinical 
diagnostic applications as an MRI contrast agent. The relaxivity plots of IOs and IOs 
loaded PLGA-mPEG nanoparticles are given in Figure 15 and a summary of the 
relaxivities in Table 2. The nanoparticles developed in this project are almost twice 
more efficient than the commercial IOs Resovist® based on their in vitro r2 and r2* 
data. Using the simulated results by Gillis et al. (2002), we can estimate the 
maximum R2* relaxation rate for the IOs used here is 630s-1. Since relaxivity is 
defined as the relaxation rate for 1mM of Fe, the theoretical maximum r2* relaxivity 
is 630 1 1mM s− −⋅ . The r2* relaxivity achieved by our IO loaded PLGA-mPEG 
nanoparticles (595.7 1 1mM s− −⋅ ) falls within this upper theoretical bound, thus proves 
our results reasonable. 
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Table 3 r2 and r2* relaxivities of IOs and IOs loaded PLGA-mPEG nanoparticles. 
Sample r2 ( 1 1mM s− −⋅ ) r2* ( 1 1mM s− −⋅ ) 
IOs 283.6 288.7 




To further verify the effect of polymer encapsulation on r2 and r2* relaxivities of the 
IOs, we conducted MRI measurement on empty PLGA-mPEG nanoparticles, and 
IOs with different concentrations of empty PLGA-mPEG nanoparticles.  
 
Figure 16 shows that empty PLGA-mPEG nanoparticles could not enhance the 
proton relaxation rate as their relaxation rates for different concentrations are almost 
the same, and the relaxation rates for the mixtures of empty PLGA-mPEG 
nanoparticles with 0.2mM IOs was similar to that of the 0.2mM IOs. This result 
confirms that the encapsulation with PLGA-mPEG nanoparticles could lead to the 
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Figure 16 Relaxation rate 1/T2 and 1/T2* of IOs, empty PLGA-mPEG nanoparticles, and mixtures of 
them at different nanoparticle concentrations. 
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In vitro MR images of the nanoparticles suspended in water, in comparison with the 
raw IOs, taken at TE = 7ms as an example are shown in Table 3.  
 
Table 4 Comparison of IOs and IOs loaded PLGA-mPEG Nanoparticles (TE = 7ms). 
 
 
From images reported in Table 4, it is evident that with equal Fe concentration, IOs 
loaded PLGA-mPEG nanoparticles give lower proton T2 and T2* relaxation times 
than IOs do. This might be due to the enhanced Ms of the IOs in the polymer matrix, 
which results in the increase in r2 and r2* relaxivities.   
 
4.2.2 Ex vivo MRI 
The T2 and T2* relaxation time lowering properties of the IOs loaded PLGA-mPEG 
nanoparticles as an MRI contrast agent is further proved by the ex vivo MRI study. 
As shown in Figure 17, a darker image of the liver of the rat injected with the 
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nanoparticles is obtained, thus demonstrating the efficacy of these nanoparticles in 
enhancing proton relaxation rate ex vivo. It could be concluded that the IOs loaded 
PLGA-mPEG nanoparticles could be used as a liver MRI contrast agent, which is 
save, biocompatible and efficient. Together with Lee et al.’s work (2004), which 
reported the possibility of encapsulating ferrofluid into PLGA particles as a kidney 
MRI contrast agent for rabbit, our project shows the great potential of IOs loaded 




Figure 17 MR imaging of the livers of the rats: upper is the control, and bottom is that of the rat 
injected with IOs loaded PLGA-mPEG nanoparticles. 
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Chapter 5 QDs loaded PLGA Nanoparticles as Fluorescent 
Probe 
 
5.1  Physicochemical Characteristics of the Nanoparticles 
5.1.1 Particle size and size distribution 
Size distribution of the red emission hydrophobic QDs loaded PLGA nanoparticles is 
given in Figure 18. These nanoparticles are relatively uniform with an average 
hydrodynamic diameter of 277.6nm.  
 
 















QDs loaded PLGA nanoparticles
 
Figure 18 Particle size distribution of QDs loaded PLGA nanoparticles. 
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5.1.2  Surface morphology 
Surface morphology of the QDs loaded PLGA nanoparticles was captured using 




Figure 19 FESEM image of QDs loaded PLGA nanoparticles. 
 
AFM in Figure 20 reveals the 3D morphology and surface structure of the 
nanoparticles. It could be found that the surface of the nanoparticles is smooth, but 
some researchers have done single particle zoom in (Mu & Feng, 2003) and particle 
sectioning analysis (Feng & Huang, 2001), which demonstrate the existence of 
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complex topography, such as micro-caves and pores, on the surface of the 
nanoparticles. The estimated particle size from the AFM image agrees with that 
measured by LLS and FESEM. 
 
 
Figure 20 AFM image of QDs loaded PLGA nanoparticles. 
 
5.1.3 Localization of QDs in PLGA nanoparticles by TEM 
Figure 21a is a TEM image of the QDs, whose diameter is around 10nm. Figure 21b 
shows one single nanoparticle with several QDs (the dark domains) encapsulated 




Figure 21 TEM images: (a) QDs, (b) QDs loaded PLGA nanoparticles. 
 
5.1.4 Localization of QDs in PLGA nanoparticles by CLSM 
Red emission hydrophobic and green emission hydrophilic QDs co-loaded PLGA 
nanoparticle suspension was observed under CLSM, and images were taken from 
both red channel (Figure 22a) and green channel (Figure 22b). Imaging software, 
Fluoview 4.3, was used to merge these two images into one, as shown in Figure 22c. 
Most of the red dots and green dots co-localize, which indicates that both QDs have 
been successfully encapsulated into the PLGA nanoparticles. Otherwise, they could 
not be together because of their contrary surface properties. Some dots do not co-
localize well due to the non-homogeneous encapsulation of these two QDs in the 
matrix and the Brownian motion of the nanoparticles in the aqueous phase, 
especially for smaller ones. Both this study and the TEM image prove that the QDs 
have been successfully encapsulated into the PLGA nanoparticles. 
 60
 
   
Figure 22 Confocal microscopic images of red emission hydrophobic and green emission hydrophilic 
QDs co-loaded PLGA nanoparticles suspension: (a) image from red channel, (b) image from green 
channel, (c) merged image. 
 
5.1.5 Fluorescence emission spectrum 
Figure 23 shows the fluorescence emission spectra of the QDs in n-decane and  
nanoparticles aqueous suspension. The sharp emission spectrum of the QDs is well 
preserved after the polymer encapsulation and is similar to that of free QDs in n-
decane. This is reasonable as the QDs were encapsulated into the hydrophobic PLGA 
matrix, which might not change the optical properties much (Pinaud et al., 2006). 
However, the emission peak of the encapsulated QDs is blue-shift from 655nm to 
650nm, which might be due to the polarity change of the solvents and slight change in 
band gap energy of the QDs (Kwon & Okano, 1996).   
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 QDs loaded PLGA nanoparticles
 
Figure 23 Fluorescence emission spectra of QDs in n-decane and QDs loaded PLGA nanoparticle 
aqueous suspension. 
 
5.2 Cellular and Animal Experiments  
5.2.1 Cell uptake   
To give direct evidence that the QDs loaded PLGA nanoparticles have gone into the 
cells instead of just attaching to them, CLSM was used to visualize the internalization 
of the nanoparticles by MCF-7 cells. The nuclei of cells were stained blue with DAPI 
while the nanoparticles have a fluorescence of red because of the red emission QDs 
inside. As shown in Figure 24, the nanoparticles have been internalized to the cells 
but appeared non-homogeneously distributed in the cytoplasm or probably 
accumulated in endocytic vesicles (Pinaud et al., 2006). No red fluorescence could be 
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detected by the control cells either not exposed to the nanoparticles or incubated with 
the empty nanoparticles (data not shown). 
 
 
Figure 24 Confocal microscopic images of MCF-7 cells after 2h incubation with QDs loaded PLGA 
nanoparticles at 37 ◦C: (a) image from combined blue channel and red channel, (b) image from 
combined blue channel, red channel and bright field. 
 
5.2.2 Ex vivo fluorescence imaging 
Although in vitro cellular experiment has shown great potential for QDs loaded 
PLGA nanoparticles to be uptaken by cells and realize cellular imaging, it is still 
necessary to carry out animal study. 1h after the injection, rats were sacrificed and 
dissected, and various tissues were fixed and then cut into slices. The prepared tissue 
slices and drops of blood on the glass slides were observed under CLSM. Obvious red 
fluorescence signals could be found in blood, liver and spleen. While the control 
group shows no fluorescence under the condition (data not shown). This study gives 
direct evidence that QDs loaded PLGA nanoparticles delivered intravenously have 
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the potential to be used as a fluorescent probe for cellular and biomolecular imaging 
which would benefit cancer diagnosis a lot.  
 
Figure 25 Ex vivo CLSM images of QD loaded PLGA nanoparticles in SD rat 1h after tail vein 
injection (bar = 5µm). 
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Chapter 6 Comparison of QDs Loaded Nanoparticles of 
Different Biocompatible and Biodegradable Polymers 
 
6.1 Comparison of Physicochemical Properties of the Nanoparticles  
6.1.1 Particle size and size distribution 
Size and size distribution of the QDs loaded nanoparticles made of different polymers: 
PLGA (emulsified by PVA), PLGA (emulsified by VE TPGS), and PLGA-TPGS 
(emulsified by PVA) were measured by LLS and compared as shown in Figure 24 
and Table 4. 
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QDs loaded PLGA-TPGS nanoparticles (emulsified by PVA)
Mean Diam. = 376.5nm
(c)
 
Figure 26 Size distribution of QDs loaded polymeric nanoparticles. 
 
A relatively narrow size distribution is achieved for all the three formulations. VE 
TPGS emulsified nanoparticles have a larger particle size than the other two 
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formulations. This may be due to the different capability of VE TPGS and PVA in 
stabilizing the oil droplets in aqueous phase. However, if the concentration of the 
emulsifiers used in the fabrication (0.06% for VE TPGS and 0.5% for PVA) is 
considered, the efficiency of VE TPGS still seems high. 
 
Encapsulation efficiency (EE) is defined as the ratio of actual and theoretical amount 
of QDs loaded in the nanoparticles as follows: 
100%actual amount of QDs loaded in nanoparticlesEE
theoreticalamount of QDs loaded in nanoparticles
= ×  
 
From Table 5, the EE of QDs is low (~10%) if compared with that of normal drugs, 
some of which can even attain 100% (Ruan et al., 2002; Zhang & Feng, 2006). This 
is probably because of the big particle size and high density of the QDs. 
 
Table 5 Properties of the QDs loaded polymeric nanoparticles. 
Polymer Emulsifier Mean Diam. (nm) EE (%) 
PLGA PVA 269.4 11.6 
PLGA TPGS 426.21 11.5 
PLGA-TPGS PVA 376.5 9.7 
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6.1.2 Zeta potential 
All the three formulations have negative surface charge as depicted in Table 6, 
attributed to the presence of ionized carboxyl groups on the surface of the 
nanoparticles (Sahoo et al., 2002). Zeta potential of PVA emulsified PLGA 
(PLGA/PVA) nanoparticles is -15.69mV, VE TPGS emulsified PLGA (PLGA/VE 
TPGS) nanoparticles is -21.15mV, and PVA emulsified PLGA-TPGS (PLGA-
TPGS/PVA) nanoparticles is -14.56mV. These values are less negative than the 
literature data of the naked PLGA, which is -45mV (Stolnik et al., 1995). This 
reduction in surface charge could be resulted from the shielding effect of the 
remaining emulsifiers on the surface of the nanoparticles even though washing has 
been carried out three times.  
 
Table 6 Zeta potential of QDs loaded polymeric nanoparticles. 
Polymer/ Emulsifier  
PLGA/PVA PLGA/TPGS PLGA-TPGS/PVA 
Mean (mV) -15.69  -21.15  -14.56  
SD (mV) 1.29  0.75  0.22  
 
6.1.3 Surface morphology 
Besides particle size and surface charge of the nanoparticles, surface morphology is 
also important because it determines QDs release kinetics from the nanoparticle 
 68
formulations. FESEM and AFM show general and fine morphology of the 
































Figure 27 FESEM images of QDs loaded polymeric nanoparticles. 
 
The nanoparticles are spherical and moderately uniform. There is no significant 
difference in surface morphology of the three formulations. But some 





























Figure 29 shows TEM images of all the three formulations. It is clear that QDs have 
been successfully encapsulated into the polymer matrix, but some are just attached 
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to the surface of the nanoparticles. The TEM images tally well with those observed 
by FESEM and AFM. 
 
 






































6.1.5 In vitro release 
The in vitro release profile shown in Figure 30 indicates that only a small percentage 
of QDs is released after 20 days in PBS. The maximum cumulative release observed 
is 10.2% in PVA emulsified PLGA nanoparticles, followed by 9.7% in TPGS 
emulsified PLGA nanoparticles, and lastly 3.6% in PVA emulsified PLGA-TPGS 
nanoparticles. From this, it could be concluded that the prepared QDs loaded 
polymeric nanoparticles exhibit stability in PBS, which would probably lower the 
toxicity of the raw QDs.  
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Moreover, an initial burst could be observed in both PLGA nanoparticle 
formulations (either emulsified by PVA or TPGS), which is followed by an 
approximately first-order release, whereas PVA emulsified PLGA-TPGS 
nanoparticles displayed a long induction period followed by a slow and sustained 
release. This can be explained by the different hydrophilic properties of the two 
polymers. In PLGA-TPGS nanoparticles, hydrophilic component TPGS tends to be 
at the surface of the matrix and thus forms a hydrophilic layer, which prevents the 
diffusion of QDs from hydrophobic core to the release medium. 
 


























Figure 30 In vitro release of QDs loaded polymeric nanoparticles in PBS. 
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However, in vivo release profile of the QDs from the nanoparticles would not 
necessarily be similar to that of in vitro as in vitro release study is not able to 
simulate all the metabolic processes which will occur in the body. In order to further 
verify the real release of the nanoparticle formulations, cell culture medium DMEM 
was used.  
 

































After 10 days, the maximum cumulative release in cell culture medium is found to be 
40.7% in PVA emulsified PLGA nanoparticles, followed by 12.0% in TPGS emulsified 
PLGA nanoparticles, and lastly 9.2% in PVA emulsified PLGA-TPGS nanoparticles. The 
release in cell culture medium is much higher than that observed in PBS for each 
nanoparticle formulation, which could be explained by the fact that cell culture medium 
contains amino acids, antibiotics and enzymes that might speedup the destabilization and  
degradation of the nanoparticles.  
 
The release trends are similar in PBS and cell culture medium: PVA emulsified PLGA-
TPGS nanoparticles have the slowest release in vitro. This is an advantage of these 
PLGA-TPGS/PVA nanoparticles verse the conventional PLGA nanoparticles, as slow 
release would reduce the toxicity of the QDs.  
 
6.2 Cellular and Animal Experiemtns 
6.2.1 Cell uptake 
The diagnostic efficiency of the QDs loaded polymeric nanoparticles depends on their 
internalization and sustained retention by the malignant cells. Although in vivo and in 
vitro biological process would be different, an in vitro cell uptake study can give some 






























Figure 32 MCF-7 cell uptake of QDs loaded polymeric nanoparticles (Incubation time = 2 h). 
 
It could be observed in Figure 32 that VE TPGS emulsified PLGA nanoparticles have 
higher cell uptake efficiency than PVA emulsified PLGA nanoparticles at the 
nanoparticle concentrations of both 250µg/ml and 500µg/ml after 2h incubation. PLGA-
TPGS nanoparticles (emulsified by PVA) show highest cell uptake efficiency among all 
the three formulations, 36% and 29% at the nanoparticle concentrations of 250µg/ml and 
500µg/ml, respectively. Similar trends are found for cells incubated with the nanoparticle 
































Figure 33 MCF-7 cell uptake of QDs loaded polymeric nanoparticles (Incubation time = 24 h).  
 
Note that cell uptake efficiency at lower nanoparticle concentration 250µg/ml is higher 
than that at 500µg/ml for both incubation durations. This is expected. The number of the 
cells present initially in each well is approximately the same and the number of 
nanoparticles that could be uptaken by these cells should also be the same, while the total 
amount of the nanoparticles present at the higher concentration is higher. Therefore, 
when expressed as percentage, the cells incubated with higher nanoparticle 
concentrations will have a lower value of the cell uptake efficiency. 
 
Error! Reference source not found. shows the confocal microscopic images of MCF-7 
cells after 2h incubation with QDs loaded polymeric nanopartciles at 37◦C. The red 
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emission QDs loaded polymeric nanoparticles were uptaken by cells and located closely 














Figure 34 Confocal microscopic images of QDs loaded polymeric nanoparticles.
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6.2.2 Cell viability 
The chemical components of the QDs core, such as Cd, are highly toxic. It is known that 
Cd ions will be released when the QDs are destroyed through a variety of pathways. The 
normally used ZnS coating could only reduce the toxicity to a certain extent. To further 
reduce the toxicity of the QDs, one of the objectives of this project, biocompatible 
polymers were used to encapsulate the raw QDs and then the cytotoxicity of the 
nanoparticle formulations was investigated. However, the hydrophobic QDs suspended in 
organic solvent n-decane could not be used to as a control because the cells will die 
definitely if incubated together with the organic solvent.  
 
The cytotoxicity of the three formulations are very low as presented in Figure 35. The 
percentage of viable cells remains high after 24h incubation with the QDs loaded 
polymeric nanoparticles even at high nanoparticle concentration of 250µg/ml. PLGA-
TPGS nanoparticles have the highest cell viability at high nanoparticle concentration. 
Thus, this polymer encapsulation makes the hydrophobic QDs possible to be uptaken by 
cells with low cytotoxicity and the nanoparticles could be used as a potential fluorescent 




































Chapter 7 Conclusions and Recommendations 
 
7.1 Conclusions 
This study demonstrates that the encapsulation of IOs into nanoparticles of biocompatible 
and biodegradable polymer PLGA-mPEG leads to an enhanced MRI contrast efficiency 
compared with Resovist®, the commercial IO contrast agent. FESEM & TEM images and 
Fe content measured by ICP-MS show a strong evidence of the presence of IOs within 
the nanoparticles. These nanoparticles render an increase in Ms and r2 & r2* relaxivities 
of the IOs, resulting in a strong enhancement in MRI contrast effect. This suggests the 
nanoparticles be a promising formulation for MRI contrast agent.  
 
QDs loaded PLGA and PLGA-TPGS nanoparticles using different emulsifiers (PVA and 
VE TPGS) were prepared and characterized by various techniques. The experimental 
results show that all the three kinds of nanoparticles are spherical, uniform and stable. 
TEM images indicate that the QDs have been successfully encapsulated into the polymer 
matrix. In vitro release study shows that PLGA-TPGS nanoparticles (emulsified by PVA) 
have the slowest release in cell culture medium as well as in PBS. This is very important 
to the biomedical applications of these nanoparticle formulations because the less the 
QDs released into the surrounding medium, the smaller the cytotoxicity of the 
nanoparticles, which agrees well with the cell viability results. Moreover, the PLGA-
TPGS nanoparticles attain the highest cell uptake efficiency among the three 
formulations. Therefore, it could be concluded that polymer PLGA-TPGS performs well 
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for the encapsulation of raw QDs and the prepared nanoparticles have the potential as a 
fluorescent probe in cellular and biomolecular imaging. 
  
7.2 Recommendations 
In the study of superparamagnetic IOs loaded PLGA-mPEG nanoparticles as MRI 
contrast agent, due to time constraint, we only did some preliminary ex vivo MRI 
research on the nanoparticles. A direct comparison of in vivo MR imaging of IOs and IOs 
loaded PLGA-mPEG nanoparticles in rats was unable to be done. Thus, we suggest that 
in the future, in vivo MRI and further quantitative bio-distribution study of the 
nanoparticles in animals should be carried out to verify the efficiency of the developed 
nanoparticles as contrast agent.  
 
In the study of QDs loaded polymeric nanoparticles as fluorescent probe, quantitative 
bio-distribution study of the nanoparticles is recommended. Moreover, it is also good to 
conduct in vivo fluorescence imaging of the whole rats by using a macro-illumination 
system designed specifically for small animal studies (Gao X et al., 2004), to investigate 
the potential of the nanoparticles as biomedical fluorescent probe thus further study could 
be designed accordingly to improve the nanoparticle formulation.  
 
In the field of drug delivery, therapeutic drugs together with the IOs or QDs can be 
encapsulated into the matrix of biocompatible and biodegradable polymers with certain 
ratio. Thus quantification of the drug can be carried out by measuring the MRI or 
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fluorescence signal of the nanoparticles. This way, the pathway of the drugs could be 
tracked and the amount of the drugs to be delivered could also be controlled.  
 
In the field of surgery, there is an ongoing interest in the development of magnetic-
fluorescent diagnostic agents, termed as multimodal imaging probes. By correlating the 
ultrasensitive optical imaging capability of QDs with MRI, a surgeon could identify and 
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